Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Burden of Disease in Myasthenia Gravis (Mya-BoD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03979521
Recruitment Status : Active, not recruiting
First Posted : June 7, 2019
Last Update Posted : August 9, 2019
Sponsor:
Collaborator:
NeuroCure Clinical Research Center, Charite, Berlin
Information provided by (Responsible Party):
Andreas Meisel, Charite University, Berlin, Germany

Brief Summary:
Questionnaire-based survey addressed to german patients with the chronic autoimmune muscle disease called myasthenia gravis regarding quality of life, socioeconomic impact, social support, course of disease, complications of therapy and psychological comorbidities.

Condition or disease
Myasthenia Gravis

Detailed Description:

Background:

Myasthenia gravis is a rare, chronic, antibody-mediated autoimmune disease that results in muscular weakness. The patients suffer from symptoms such as visual disturbances (especially double vision), weakness in the arms and legs, chewing and swallowing disorders and respiratory disorders, as well as crisis-related worsening of ventilation. This is often accompanied by pronounced fatigue (physical) and mental fatigue (depression).

Despite drug therapies that are on one hand symptomatic improving muscle strength, and on the other hand modulating the immune system, as well as specific procedures and drugs used in crises (plasmapheresis, immunoglobins) or refractory patients, patients are often severely limited, affecting everyday activities of self-care, family, social and professional life, thus affecting the mood and quality of life of patients. There is a lack of data measuring quality of life adequately.

Aim:

The aim of the data collection is to record the quality of life of myasthenia patients. By clinical information on the disease (including symptoms, course and therapy) and recording the social and occupational situation, the data should be contextualized. The following hypotheses are to be confirmed:

Primary hypotheses

  • Myasthenia gravis affects the quality of life of patients comparable to neurological diseases such as multiple sclerosis
  • Patients are limited in their participation in their private and professional life
  • The severity of the disease is associated with the quality of life. Secondary hypotheses
  • Myasthenia is associated with income busses and other economic disadvantages of the night
  • Quality of life in myasthenia patients is related to fatigue and depression
  • Quality of life in myasthenia patients depends on different therapy methods
  • Myasthenia gravis has an impact on family planning and care for children.

Methods:

In cooperation with the German Myasthenia Gravis Society, a questionnaire prepared by the Charité will be sent to its members with a request for completion and an anonymous return. Similar projects have already been implemented in the past (response rate> 30%). About 3,300 patients should be contacted.

The returned questionnaires are then statistically evaluated and presented as part of a publication. For the evaluation of the hypotheses suitable descriptive, univariate analysis methods are used. Furthermore, with sufficient case numbers, multivariate analyzes (e.g., logistic regression) are also planned.

The questionnaire contains general information and questions about:

  • Education and employment
  • Social situation
  • Social Support
  • Economic aspects
  • Symptoms and severity, course, treatment of myasthenia
  • Quality of life
  • Fatigue and depression

Layout table for study information
Study Type : Observational
Actual Enrollment : 1680 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Questionnaire Survey on the Systematic Recording and Characterization of Quality of Life Limitations in Myasthenia Gravis
Actual Study Start Date : May 1, 2019
Actual Primary Completion Date : July 31, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Questionnaire for self-completion by patients containing questions about general information, information on myasthenia, information socioeconomic situation [ Time Frame: directly after inclusion in the study ]
  2. Hospital Anxiety and Depression Scale (HADS) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients to determine the levels of anxiety and depression

  3. Mya Quality of Life 15 (Mya QoL15) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients for use as a measure of health outcome

  4. Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF36) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients for patients health

  5. Myasthenia gravis Activities of daily living (MG ADL) [ Time Frame: directly after inclusion in the study ]
    Questionnaire for self-completion by patients to determine symptom severity and limitations in activities of daily living



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Myasthenia Gravis being member at the German myasthenia gravis socitey (Deutsche Myasthenie Gesellschaft)
Criteria

Inclusion Criteria:

  • Patients with Myasthenia Gravis
  • Age ≥18 years

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03979521


Locations
Layout table for location information
Germany
NeuroCure Clinical Research Center (NCRC), Charité University, Berlin
Berlin-Mitte, Germany
Sponsors and Collaborators
Charite University, Berlin, Germany
NeuroCure Clinical Research Center, Charite, Berlin
Investigators
Layout table for investigator information
Principal Investigator: Andreas Meisel, Prof. Dr. med. Charite University, Berlin, Germany

Layout table for additonal information
Responsible Party: Andreas Meisel, Prof. Dr. med., Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT03979521     History of Changes
Other Study ID Numbers: Mya-BoD
First Posted: June 7, 2019    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Andreas Meisel, Charite University, Berlin, Germany:
Myasthenia Gravis
Quality of life
Burden of disease
Social support
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Weakness
Myasthenia Gravis
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Signs and Symptoms
Autoimmune Diseases of the Nervous System
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases